The design of a highly efficient Phase IIb clinical trial in stroke in which the most vulnerable stroke patients are treated with the most promising therapy. The trial starts by testing the drug that had the strongest pre-clinical signal, DDFPe, which targets the top of the chain of events and hits that target quickly and effectively. Next, it seeks to test patients with severe strokes where there is the most room to show improvement. Third, it maximizes the duration of protection to provide greater impact on the patients. Other elements improve clinical signal further.